viewNetscientific PLC

NetScientific PLC - Issue of Equity

RNS Number : 8547W
NetScientific PLC
21 August 2020

NetScientific plc

("NetScientific" or the "Company")

Issue of Equity

NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that to ensure that the number of Interim Ordinary Shares is exactly divisible by 10 to allow for a capital reorganisation which has the effect of consolidating ten Existing Ordinary Shares into one New Ordinary Shares and as previously announced on 5 August 2020, it is proposed that Neville Registrars is issued with 4 Existing Ordinary Shares after the General Meeting and before the Record Date, at which point the 4 Existing Ordinary Shares will be consolidated off the register immediately.

Immediately following the capital reorganisation becoming effective, the number of New Ordinary Shares will be 7,856,187.

Unless other defined, terms used in this announcement shall have the same meanings as those defined in the announcement dates 5 August 2020.

For more information, please contact:


Ilian Iliev, CEO  Tel: +44 (0)20 3514 1800

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Jessica Cave / Darshan Patel  Tel: +44 (0)20 7220 1666

MO PR ADVISORY (Press Contact)

Mo Noonan  Tel: +44 (0)78 7644 4977

About NetScientific

NetScientific PLC is a transatlantic healthcare IP commercialisation Group focused on technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people.

For more information, please visit the website at    www.NetScientific.net


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Netscientific PLC

Price: 57

Market: AIM
Market Cap: £8.5 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read